ArticleEuropean journal of pediatrics2026
Phenotypic characterization of treatment-naïve childhood asthma with obesity: features of lung function, inflammation, and lipid profiles.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overweight and obesity are associated with poorer treatment response and impaired pulmonary function in children with bronchial asthma: a retrospective study.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo characterize the multidimensional phenotype of childhood asthma associated with obesity at initial diagnosis, prior to controller therapy.
methodsWe conducted a cross-sectional study of 130 treatment-naïve children with asthma, comprising 67 with normal weight and 63 with obesity. All participants underwent spirometry, assessment of inflammatory biomarkers, and immune cell profiling. Lipid profiles were measured solely in the obese subgroup (n = 63) to evaluate metabolic comorbidity. The Type 2 (T2)-high inflammatory phenotype was defined using standard clinical cut-offs (blood eosinophil count ≥ 0.3 × 10⁹/L and/or FeNO ≥ 20 ppb); dyslipidemia was defined according to the 2012 National Cholesterol Education Program (NCEP) criteria.
resultsCompared to children with normal-weight asthma, those with obesity showed early airflow obstruction, with reductions in forced expiratory volume in 1 s (FEV₁%), the FEV₁/forced vital capacity (FVC) ratio, mid-expiratory flow (MMEF%), and peak expiratory flow (PEF%), but preserved FVC. Multivariable analysis confirmed this obstruction was independently associated with obesity after adjusting for age, sex, and T2-inflammatory status. The obese asthma group also presented elevated neutrophil counts, reduced regulatory T-cell (Treg) percentages, and a lower prevalence of the T2-high phenotype, despite a similarly high burden of clinical atopy and elevated serum total immunoglobulin E (IgE). Furthermore, over half (56%) of the obese group had dyslipidemia at diagnosis.
conclusionAt asthma diagnosis, obesity defines a phenotype characterized by early airflow limitation, a T2-low inflammatory tendency, and frequent metabolic dysregulation. Obesity itself is a primary, independent determinant of this lung function impairment. These findings establish a critical phenotypic baseline for future longitudinal studies aimed at enabling personalized management of childhood asthma complicated by obesity. WHAT IS KNOWN: • The association between obesity and asthma in children is recognized as a distinct clinical entity associated with more severe disease and poorer outcomes. Comprehensive baseline data integrating lung function, inflammatory profiles, and metabolic status are scarce for children with obesity related asthma in a treatment-naïve state. WHAT IS NEW: • At asthma diagnosis, treatment-naïve children with obesity present a distinct phenotype characterized by 1) early airflow obstruction, 2) a frequent T2-low inflammatory signature (with elevated neutrophils), and 3) a high prevalence of dyslipidemia-despite a high background of clinical atopy. Obesity itself is a primary, independent determinant of this early lung impairment. These findings establish a critical baseline profile, underscoring the need for multidimensional assessment to stratify risk and guide clinical decision-making in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.